Drugs / GSK2186877A
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00992784 | Oct 2009 → May 2010 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00938392 | Jul → Oct 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00765076 | Oct 2008 → Dec 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00772889 | Oct 2008 → Dec 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00760617 | Oct 2008 → May 2009 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT00753272 | Sep 2008 → Jun 2010 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GSK2186877A | “Observer-blind Safety and Immunogenicity Study of GlaxoSmithKline Biologicals' Influenza Vaccine GSK2186877A When Administered to Elderly Subjects” NCT00992784 ↗ |
| Modality | Vaccine | “influenza vaccine GSK2186877A” NCT00772889 ↗ |
| Route | Intramuscular | “One intramuscular injection at Day 0” NCT00765076 ↗ |